1. Blocking interleukin-23 ameliorates neuromuscular and thymic defects in myasthenia gravis
- Author
-
José A. Villegas, Jérôme Van Wassenhove, Judith Merrheim, Karen Matta, Samy Hamadache, Clémence Flaugère, Pauline Pothin, Frédérique Truffault, Sébastien Hascoët, Nicola Santelmo, Marco Alifano, Sonia Berrih-Aknin, Rozen le Panse, and Nadine Dragin
- Subjects
Autoimmunity ,Inflammation ,Neuromuscular junction ,Germinal centers ,Th17 ,Muscle regeneration ,Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Acetylcholine receptor (AChR) myasthenia gravis (MG) is a chronic autoimmune disease characterized by muscle weakness. The AChR+ autoantibodies are produced by B-cells located in thymic ectopic germinal centers (eGC). No therapeutic approach is curative. The inflammatory IL-23/Th17 pathway is activated in the thymus as well as in the blood and the muscle, contributing to the MG pathogenic events. We aimed to study a potential new therapeutic approach that targets IL-23p19 (IL-23) in the two complementary preclinical MG models: the classical experimental MG mouse model (EAMG) based on active immunization and the humanized mouse model featuring human MG thymuses engrafted in NSG mice (NSG-MG). In both preclinical models, the anti-IL-23 treatment ameliorated MG clinical symptoms. In the EAMG, the treatment reduced IL-17 related inflammation, anti-AChR IgG2b antibody production, activated transduction pathway involved in muscle regeneration and ameliorated the signal transduction at the neuromuscular junction. In the NSG-MG model, the treatment reduced pathogenic Th17 cell population and expression of genes involved in eGC stabilization and B-cell development in human MG thymus biopsies. Altogether, these data suggest that a therapy targeting IL-23p19 may promote significant clinical ameliorations in AChR+ MG disease due to concomitant beneficial effects on the thymus and skeletal muscle defects.
- Published
- 2023
- Full Text
- View/download PDF